Clinical Efficacy and Safety of Baricitinib in Patients With Alopecia Areata in Korea

This study evaluated the efficacy and safety of baricitinib in 117 Korean patients with alopecia areata (AA) over 36 weeks, showing significant hair regrowth with 55.4% of patients with severe AA achieving a SALT score of 20 or less. Patients with less severe AA experienced greater improvements. Adverse reactions were mild to moderate, affecting 16.8% of patients. The study concludes that baricitinib is a well-tolerated and effective treatment for treatment-resistant AA, with potential enhanced effectiveness when combined with therapies like corticosteroids and minoxidil. Further research is needed to assess long-term effects and compare with other treatments.